Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Does yesterday's offering eliminate any chance of Big Pharma purchasing HGEN or lenz anytime soon?
Could everyone hold off on buying for the rest of the day? I have money coming in tomorrow and I want to buy at these heavily discounted prices. TIA.
Lenzilumab is about to become the drug of choice for all severe patients around the world. They need to massively increase production. That costs money. I know people will say they that had all of that secured. But things weren't really going to get ramped up until an EUA or at least good data.
Here is an article from March 10th talking about Thermo Fisher adding $600 million in facilities to meet Covid demand. Humanigen is talked about at the bottom.
https://www.fiercepharma.com/manufacturing/thermo-fisher-lays-out-600m-to-more-than-double-capacity-for-biologics-and-vaccines
As an investor I was trying to be honest with myself about lenzilumab's chances at an EUA. The number I came up with is 95%. Lenzilumab met its primary endpoint. It did it for serious patients and there is no drug currently available that has good efficacy with severe patients. And then add to that Janet Woodcock being in control of OWS when lenz was chosen for government funding, I just don't see it getting rejected.
The data that Humanigen put out is for the entire trial. Other drugs are trying for an EUA based on slices of their trial. The best attack the hit pieces could come up with against lenz is that 33 patients were excluded from the trial because they didn't receive a dose. Why in the world would someone be included in the trial data if they didn't receive either lenzilumab or the placebo? And trial protocol excluded them from the beginning because that was the FDA guidance.
We've waited this long. We can wait a few more weeks. And now owning HGEN is almost stress free. Before the UK study confirming GM-CSF's role in Covid, I was super stressed. I was impressed with Chappell and Durrant but I was having to put a lot of faith in them. Then the UK study came out and I gained a ton of confidence that the trial would be a success. Now we've seen topline data. Data is great. Lenz will get an EUA. I have zero stress right now. The stock is virtually risk free.
CytoDyn's leronlimab decreases mortality by 82% among critically ill coronavirus patients after two weeks in CD12 trial
https://www.proactiveinvestors.com/companies/news/945330/cytodyn-s-leronlimab-decreases-mortality-by-82-among-critically-ill-coronavirus-patients-after-two-weeks-in-cd12-trial-945330.html
Hey underwater Shorts who are now starting the due diligence they should have done BEFORE their investment. Lenzilumab will get an EUA. You don't have long to get out.
Below are links to help you understand the importance of GM-CSF
https://www.bbc.com/news/health-56352128
https://www.dailymail.co.uk/news/article-9346955/Blood-test-spot-Covid-patients-high-risk-dying.html
https://immunology.sciencemag.org/content/6/57/eabg9873
CytoDyn's new results are the very definition of datamining. Why don't they give us the number of patients that died in each arm? It is probably something like 3 patients died in the treatment arm and 1 patient died in the placebo arm at 14 days. And then the trend reversed.
These low prices are a blessing to anyone adding. You get to know data before buying. It's not fair to those of us who bought without advance knowledge of data. This stock is literally zero risk right now.
I can't get over the weakness of STAT news article attack. 33 patients didn't receive either treatment or placebo. Not one dose. Trial protocol stated that they would be excluded. It makes sense to exclude them. Biggest nothing burger ever.
Data is great. That will take care of everything. Maybe we'll have to wait 2-3 weeks for an EUA to get what is coming. I can wait.
That STAT news article is such a nothing burger. They clearly wrote it with ulterior motives. And the veracity is irrelevant because people will sell stock when STAT releases a hit piece because the stock price always goes down immediately after release. Greasy.
I can just imagine all of the research that the Shorts are doing right now. A lot of biotech investors don't delve deeply into the science of the individual stocks they are invested in. They have too much going on to spend a lot of time on one stock's minutiae. I bet they make time for GM-CSF tonight.
Below are links to understand GM-CSF and Covid
https://www.bbc.com/news/health-56352128
https://www.dailymail.co.uk/news/article-9346955/Blood-test-spot-Covid-patients-high-risk-dying.html
https://immunology.sciencemag.org/content/6/57/eabg9873
There are some bigtime investors doing due diligence as we speak. And anyone doing due diligence on Cameron Durrant and Dale Chappell is going to come away impressed. We have none of the red flags that normally exist in Small Pharma. HGEN's stock price is still seriously undervalued because our two leaders are science-first guys who did nothing to pump the stock. HGEN's rise to $30-$100 is still to come this week.
I can't believe I wasted my whole weekend on the CYDY board trying to convince them the importance of GM-CSF and that they should sell CYDY to buy HGEN. I posted 50+ times. What a colossal waste of time. And moneycrew informed me that Charlie Sheen is going to sue me for defamation of character. Can someone sue you for defamation of character when they have no character?
This song is dedicated to everyone who was short HGEN: